Airbus recorded orders and options for 123 planes, according to the aviation consulting firm IBA.iQ.Paris Air Showread more
Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
The Pentagon said that the crew of one of the tankers, the Japanese Kokuka Courageous, found an unexploded limpet mine on its hull following an initial explosion.Politicsread more
Eleven banks that lend to shipping lines announced Monday that climate impact will be integrated into the criteria that determines how much shipping companies can borrow, an...Transportationread more
"The recent Iranian attacks validate the reliable, credible intelligence we have received on hostile behavior by Iranian forces," Shanahan says.Politicsread more
"They're fun. They're companies you know or can learn about," he said, "and you can happily buy them into weakness if you've done the homework and you believe in their...Mad Money with Jim Cramerread more
"The idea that you can put it in dog food and it's going to calm your dog ... I think that's pretty hokey," former FDA chief Scott Gottlieb says.Health and Scienceread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
Federal antitrust regulators are eyeing big drugmaker Mylan's EpiPen business, the company said Monday.
Mylan, in a statement, said the Federal Trade Commission asked it "months ago" for information about its anti-allergy EpiPen "as part of a preliminary investigation."
The disclosure comes nearly five months after two United States senators asked the FTC to investigate whether Mylan violated antitrust laws to protect the auto-injector EpiPen from competition.
Those lawmakers' interest in EpiPen in turn was sparked by consumer outrage over Mylan having raised the price of the device more than 500 percent in recent years, to more than $600 per two-pack.
"Mylan received an information request from the FTC months ago as part of a preliminary investigation," said Mylan spokeswoman Nina Devlin on Monday.
"Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit," Devlin said.
"We note that the epinephrine auto-injector market is and always has been competitive, with multiple products competing on the market since we acquired EpiPen Auto-Injector."
"Further, Teva has had patent licenses to launch their proposed generic alternative to EpiPen Auto-Injector since June 2015, pending FDA approval, years prior to patent expiry, " Devlin said.
Mylan's stock was down about 1 percent in afternoon trading Monday.
New York Attorney General Eric Schneiderman last September opened his own antitrust investigation of Mylan. At the time, Schneiderman said "a preliminary review by his office revealed that the company "may have inserted potentially anticompetitive terms" into its sales contracts for Epipen "with numerous local school systems."
In October, Mylan agreed to pay a $465 million settlement with the U.S. Department of Justice to settle claims that the company shortchanged the Medicaid system by misclassigying EpiPen for the purposes of a drug rebate program.
Mylan did not admit any wrongdoing in the settlement. But before the deal was reached, a number of members of Congress had questioned whether Mylan was paying the correct rebate rate for EpiPen to the Medicaid Drug Rebate Program.
Mylan for years had classified EpiPen as a generic product for the purposes of that program. Generic drugs pay a rebate of 13 percent for sales made through Medicaid, which is the jointly run federal-state health coverage system for primarily poor people.
Brand-name drugs pay a rebate rate of at least 23.1 percent. But brand-name products whose prices rise faster than the rate of inflation can be subject to even higher rebate rates.